Persistence of preleukemic clones in acute myeloid leukemia (AML) complete remission
Lenalidomide maintenance – an active approach to treating MM?
What’s new in minimal residual disease (MRD) detection in myeloma?
Daratumumab in multiple myeloma: an overview of 3 key trials
Niels van de Donk
MRD negativity and its role as a predictor for CLL patient responses